Literature DB >> 2280977

Visual anomalies associated with albinism.

D J Creel1, C G Summers, R A King.   

Abstract

All mammals with hypopigmentation of the retinal pigment epithelium have abnormal visual systems. Albino mammals have been found to have: (1) reduced numbers of uncrossed optic fibers projecting to all visual centers, (2) disorganization of the pattern (lamination) of the dorsal lateral geniculate nuclei, and (3) disorganization of projections from the dorsal lateral geniculate nuclei to the visual cortex. The disorganization of central visual centers has catastrophic effects on stereovision and optokinetic nystagmus. Variable expression in oculocutaneous albinism suggests that affected individuals cannot always be identified by hypopigmentation, reduced visual acuity and nystagmus. Careful observation of foveal development in individuals even with normal vision is necessary to detect all persons with albinism. The scalp-recorded visually evoked potential designed to detect optic misrouting is the most reliable concomitant for determining albinism.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2280977     DOI: 10.3109/13816819009020979

Source DB:  PubMed          Journal:  Ophthalmic Paediatr Genet        ISSN: 0167-6784


  23 in total

1.  The clinical features of albinism and their correlation with visual evoked potentials.

Authors:  S E Dorey; M M Neveu; L C Burton; J J Sloper; G E Holder
Journal:  Br J Ophthalmol       Date:  2003-06       Impact factor: 4.638

2.  Abnormal crossing of the optic fibres shown by evoked magnetic fields in patients with ocular albinism with a novel mutation in the OA1 gene.

Authors:  L Lauronen; R Jalkanen; J Huttunen; E Carlsson; S Tuupanen; S Lindh; H Forsius; E-M Sankila; T Alitalo
Journal:  Br J Ophthalmol       Date:  2005-07       Impact factor: 4.638

3.  Transillumination of iris and subnormal visual acuity--ocular albinism?

Authors:  L Sjödell; A Sjöström; M Abrahamsson
Journal:  Br J Ophthalmol       Date:  1996-07       Impact factor: 4.638

4.  Behavioral Consequences of a Bifacial Map in the Mouse Somatosensory Cortex.

Authors:  Vassiliy Tsytsarev; Hiroyuki Arakawa; Shuxin Zhao; Alain Chédotal; Reha S Erzurumlu
Journal:  J Neurosci       Date:  2017-06-29       Impact factor: 6.167

5.  Molecular and clinical characterization of albinism in a large cohort of Italian patients.

Authors:  Annagiusi Gargiulo; Francesco Testa; Settimio Rossi; Valentina Di Iorio; Simona Fecarotta; Teresa de Berardinis; Antonello Iovine; Adriano Magli; Sabrina Signorini; Elisa Fazzi; Maria Silvana Galantuomo; Maurizio Fossarello; Sandro Montefusco; Alfredo Ciccodicola; Alberto Neri; Claudio Macaluso; Francesca Simonelli; Enrico Maria Surace
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-03-14       Impact factor: 4.799

6.  Nitisinone improves eye and skin pigmentation defects in a mouse model of oculocutaneous albinism.

Authors:  Ighovie F Onojafe; David R Adams; Dimitre R Simeonov; Jun Zhang; Chi-Chao Chan; Isa M Bernardini; Yuri V Sergeev; Monika B Dolinska; Ramakrishna P Alur; Murray H Brilliant; William A Gahl; Brian P Brooks
Journal:  J Clin Invest       Date:  2011-10       Impact factor: 14.808

7.  Clinical Insights Into Foveal Morphology in Albinism.

Authors:  Brandon K McCafferty; Melissa A Wilk; John T McAllister; Kimberly E Stepien; Adam M Dubis; Murray H Brilliant; Jennifer L Anderson; Joseph Carroll; C Gail Summers
Journal:  J Pediatr Ophthalmol Strabismus       Date:  2015 May-Jun       Impact factor: 1.402

8.  Vision in albinism.

Authors:  C G Summers
Journal:  Trans Am Ophthalmol Soc       Date:  1996

9.  Subnormal visual acuity (SVAS) and albinism in Mexican 12-13-year-old children.

Authors:  A Sjöström; M Kraemer; J Ohlsson; G Garay-Cerro; M Abrahamsson; G Villarreal
Journal:  Doc Ophthalmol       Date:  2004-01       Impact factor: 2.379

10.  The ocular albinism type 1 gene product, OA1, spans intracellular membranes 7 times.

Authors:  Michio Sone; Seth J Orlow
Journal:  Exp Eye Res       Date:  2007-08-29       Impact factor: 3.467

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.